Knight Therapeutics Receives New Coverage from Analysts at National Bank Financial (GUD)
Equities researchers at National Bank Financial started coverage on shares of Knight Therapeutics (CVE:GUD) in a research report issued on Thursday. The firm set an “outperform” rating and a C$6.50 price target on the stock. National Bank Financial’s target price would indicate a potential upside of 5.86% from the company’s current price.
Shares of Knight Therapeutics (CVE:GUD) traded up 0.95% on Thursday, hitting $5.31. 73,566 shares of the company’s stock traded hands. Knight Therapeutics has a 52-week low of $3.51 and a 52-week high of $7.24. The stock has a 50-day moving average of $5.09 and a 200-day moving average of $5.41. The company’s market cap is $412.9 million.
Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.